CD73 is regarded as a novel target for GBM immunotherapy and blocking CD73 had been shown to prolong the survival of patients with GBM receiving anti-PD-1 or anti-CTLA-4 treatment (53). This evidence concerns the gene PDCD1 and glioblastoma.